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Summary
The tumor-suppressor activity of the retinoblastoma
protein (RB) is encoded within a protein-binding
(“pocket”) domain that is targeted for mutations in all
cases of familial retinoblastoma and in many common
adult cancers. Although familial retinoblastoma is a par-
adigm for a highly penetrant, recessive model of tu-
morigenesis, the molecular basis for the phenotype of
incomplete penetrance of familial retinoblastoma is un-
defined. We studied the RB pocket-binding properties of
three independent, mutant RB alleles that are present in
the germline of 12 kindreds with the phenotype of in-
complete penetrance of familial retinoblastoma. Each
arises from alterations of single codons within the RB
pocket domain (designated “D480,” “661W,” or
“712R”). Under the same conditions, we studied the
properties of wild-type (WT) RB, an RB point mutant
isolated from a lung carcinoma sample (706F) and an
adjacent, in vitro–generated point mutant (707W). The
D480, 661W, and 712R mutants lack pocket protein-
binding activity in vitro but retain the WT ability to
undergo cyclin-mediated phosphorylation in vivo. Each
of the low-penetrant RB mutants exhibits marked en-
hancement of pocket protein binding when the cells are
grown at reduced temperature. In contrast, in this tem-
perature range, no change in binding activity is seen with
WT RB, the 706F mutant, or the 707W mutant. We
have demonstrated that many families with incomplete
penetrance of familial retinoblastoma carry unstable,
mutantRB alleles with temperature-sensitive pocket pro-
tein-binding activity. The variable frequency for tumor
development in these families may result from reversible
fluctuations in a threshold level of RB pocket-binding
activity.
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Introduction
The isolation of the retinoblastoma protein gene (RB)
(Friend et al. 1986) validated the two-hit hypothesis for
tumorigenesis (Knudson 1971) and, unexpectedly, re-
vealed that inactivation of a complex pathway, referred
to as the “RB/cyclin–dependent kinase” pathway, un-
derlies the development of both the rare retinoblastoma
cancer syndromes (MIM 180200) and a wide range of
common adult malignancies (Harbour et al. 1988; Ot-
terson et al. 1994;Weinberg 1995). In the case of familial
retinoblastoma, a defective RB copy is transmitted from
one affected parent to half of the offspring. These infants
subsequently developed highly penetrant, multifocal (bi-
lateral) tumors consistent with mathematical modeling
of mutational rates within susceptible retinal cells, which
are required to inactivate the remaining wild-type (WT)
allele (Knudson 1971). A striking exception, however,
has been the occasional families that present with the
clinical phenotype of incomplete penetrance of familial
retinoblastoma. This phenotype is characterized by the
absence of clinical disease in obligate carriers or the pres-
ence of children with unifocal tumors that are more char-
acteristic of sporadic retinoblastoma. In an effort to
quantitate these clinical observations, a disease-eye ratio
(DER) was proposed that scored for each family the ratio
of the sum of the number of eyes with retinal tumors
over the number of obligate carriers (Lohmann et al.
1994). Kindreds with classic familial retinoblastoma
characteristically show aDER score that approaches 2.0,
whereas families with incomplete penetrance had DER
scores !1.5.
Although early hypotheses had proposed immune-me-
diated or epigenetic mechanisms to explain the pheno-
type of incomplete penetrance (Char et al. 1974; Greger
et al. 1989), an important clue was the report of families
with incomplete penetrance that carried germline mu-
tations within regulatory sequences of the RB promoter
(Sakai et al. 1991; Cowell et al. 1996; Huang et al.
1998). Recent studies have shown that germline muta-
tions from other families with incomplete penetrance can
encode altered RB proteins that retain several parameters
of WT function (Kratzke et al. 1994; Otterson et al.
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1997; Sellers et al. 1998). These data, therefore, dem-
onstrate that the phenotype of incomplete penetrance
can arise either from mutations that lead to reduced or
deregulated levels of WT protein (class 1 low-penetrant
mutants) or from subtle mutations within the RB coding
sequence that result in defective proteins, which retain
partial WT activity (class 2 mutants) (Otterson et al.
1997). Although these observations suggested that the
molecular basis for incomplete penetrance is linked with
a unique type of RB mutation, they did not provide a
working model to explain the unpredictably reduced risk
of developing retinal tumors within these families. We
had previously shown that two low-penetrant missense
mutations localized to the RB pocket (D480 and 661W)
encoded a unique type of protein that exhibited defective
protein binding but that retained the ability to undergo
cyclin-mediated phosphorylation (Otterson et al. 1997).
We have now studied the functional properties of a novel
RB-pocket missense mutant (712R) linked with the phe-
notype of low penetrance. We observed that it shares
similar biochemical properties with D480 and 661W,
including the ability to undergo cyclin-mediated phos-
phorylation in vivo. Furthermore, we have shown that
each of these three pocket missense mutants, which have
now been identified in the germline of 12 different fam-
ilies with incomplete penetrance of familial retinoblas-
toma, encode unstable, temperature-sensitive pocket
protein-binding activity that can fluctuate from null to
an almost WT protein-binding pattern.
Subjects, Material, and Methods
Kindreds
For our analysis, we modified the definition of the
DER score (Lohmann et al. 1994) to distinguish between
nonproliferating retinal scars (retinomas/retinocytomas)
that are detected incidentally in asymptomatic obligate
carriers (not scored as retinal tumors) and bona fide
retinal tumors that represent a clonal expansion and
require clinical intervention.
D480.—A summary of the incomplete-penetrant ped-
igree carrying a germline D480 RB mutation (in-frame
deletion of RB codon 480, resulting from a triplet nu-
cleotide deletion) has been reported elsewhere (Lohmann
et al. 1994). The DER score for this family was 1.0, with
five obligate carriers: one unaffected, three having uni-
lateral disease, and one having bilateral disease.
661W.—Nine families with incomplete penetrance of
familial retinoblastoma and carrying a 661W mutation
(arginine-to-tryptophan substitution at RB codon 661,
resulting from a single nucleotide substitution) have been
identified (Onadim et al. 1992; Lohmann et al. 1994;
Seminara and Dryja 1994; Cowell and Bia 1998; Huang
et al. 1998). Sufficient clinical information was available
from seven of these families to calculate the DER scores:
0.6, 1.0, 0.6, 1.0, 0.33, 0.83, and 0.2.
712R.—Two separate families with incomplete pen-
etrance and carrying a germline 712R mutation (cyste-
ine-to-arginine substitution at RB codon 712, resulting
from a single nucleotide change) have been reported. No
clinical information is available for one kindred (Gallie
et al. 1995). The DER score for the other family was
0.50, with eight obligate carriers: four unaffected and
four having unilateral disease (Cowell and Bia 1998).
Protein Analysis
Amutant cDNA clone representing the 712Rwas gen-
erated by use of a PCR mutagenesis strategy with paired
sets of oligonucleotides incorporating the corresponding
mutation, to anchor the first of a two-step PCR reaction.
The amplification products were then purified and sub-
cloned into the eukaryotic expression plasmid, pCI-neo
(Promega), and were confirmed by nucleotide sequenc-
ing. The construction of vectors representing WT RB
and the mutants D480, 661W, 706F, and 707W have
been reported elsewhere (Kaye et al. 1990; Kratzke et
al. 1992, 1994; Otterson et al. 1997). In vivo cyclin-
mediated phosphorylation was assayed by cotransfect-
ing the RB expression plasmids with members of the
cyclin D or cyclin E family into an RB (/) cell line
(H2009 non–small-cell lung cancer cells) (Kratzke et al.
1993). The cells were lysed 72 h after transfection, and
extracts were subjected to sequential a-RB immunopre-
cipitation and a-RB immunoblot analysis, as described
elsewhere (Otterson et al. 1997). Pocket protein binding
of the mutant and WT RB constructs was assessed by
incubating [35S]-methionine-labeled in vitro–translated
RB proteins with a recombinant glutathione S-transfer-
ase (GST)-E2F1 fusion protein that had been prepared
and purified as described elsewhere (Kaelin et al. 1991).
Bound proteins were washed, separated by SDS-PAGE,
and subjected to autoradiography.
In Vivo Two-Hybrid–Binding Assay
RB cDNAs encoding the pocket domain (RB codons
398–792) were subcloned in-frame into the Gal4
DNA–binding domain plasmid, pGBT9 (Clontech). The
yeast strain SFY526 was transformed with the pGBT9-
RB plasmids and with a plasmid encoding the simian
virus-40 large T antigen fused to the Gal4 activation
domain (pTD1; Clontech) and was plated onto selective
media. Transformants were then either replica plated
onto fresh ()Leu/Trp plates, for the qualitative assay,
or into liquid selective media and were grown at the
indicated temperatures overnight. The qualitative b-ga-
lactosidase assays were performed as recommended by
the manufacturer (Clontech). Two independent trans-
formants for each mutant were assayed simultaneously,
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Figure 1 A, In vivo phosphorylation analysis. Plasmids encoding
WT RB (lanes 1–4), 706F mutant RB (lanes 5–8), and the incomplete-
penetrant mutant 712R (lanes 9–12) were cotransfected with the in-
dicated cyclin plasmids (D2, D3, and E) into the RB (/) tumor cell
line H2009 and were subjected to a-RB immunoblotting. Phosphor-
ylation is indicated by the slight retardation in migration of the RB
protein signal (ppRB). Protein-size marker is shown on the left. B, In
vitro E2F1 binding assay. cDNA plasmids encoding WT or the 706F
and 712R mutants were in-vitro translated with [35S]-methionine and
were subjected to SDS-PAGE analysis before (1 ml of lysate; lanes 1,
4, and 7) or after precipitation with either GST alone (10 ml of lysate;
lanes 2, 5, and 8) or GST-E2F1 fusion proteins (10 ml of lysates; lanes
3, 6, and 9).
Figure 2 A, Schematic representation of the RB protein. The
black rectangles represent the A and B domains of the RB pocket,
which is required for large T binding and for tumor suppression. The
approximate locations of the missense mutations tested in this study
are indicated. B, Activities of phenotypes. Null refers to the inacti-
vating RB mutations that characterize familial retinoblastoma and se-
lected common adult cancers. The DER is calculated as the sum of
the number of eyes clinically involved with retinoblastoma, divided by
the number of obligate carriers for each kindred, as described in the
Subjects, Material, and Methods section. Clinical data sufficient to
determine the mean DER score shown were available from only seven
families (661W) or one family (712R). References for these kindreds
are indicated in the Subjects, Material, and Methods section.
and each experiment was repeated three times. O-nitro-
phenyl b-D-galactopyranoside (ONPG) (Sigma) was
used as the substrate for the b-galactosidase quantitative
assay. One unit of b-galactosidase activity is defined as
the amount that hydrolyzes 1 mmol of ONPG to 0-
nitrophenol and D-galactose per minute per cell: b-ga-
lactosidase units = 1,000 # OD420/time (min) # vol-
ume# concentration factor# OD600. Duplicate mea-
surements of three independent yeast transformants
were assayed for each RB mutant.
Results
We recently demonstrated that two low-penetrant RB
alleles, D480 (a deletion of codon 480) and 661W (an
arginine-to-tryptophan substitution at codon 661), re-
tained the ability to undergo cyclin-dependent, kinase-
mediated phosphorylation but showed defective RB
pocket binding in vitro (Otterson et al. 1997). We have
now tested a novel RB missense mutation, 712R (cys-
teine-to-arginine substitution at codon 712), that also
localizes to the RB-pocket domain and that was iden-
tified within the germline of two independent families
with incomplete penetrance of familial retinoblastoma
(Gallie et al. 1995; Cowell and Bia 1998). Transient
transfection of an RB () carcinoma cell line with a
mammalian expression plasmid containing the 712R
substitution showed evidence for RB phosphorylation
when the 712R plasmid was cotransfected with a plas-
mid encoding either cyclin D2, cyclin D3, or cyclin E,
although the degree of hyperphosphorylation was less
than that observed for WT RB (fig. 1A). In contrast, a
plasmid expressing the 706F substitution (Kaye et al.
1990) was unable to undergo cyclin-mediated phos-
phorylation. Although the 712R protein retained the
ability to undergo cyclin-mediated phosphorylation in
vivo, it demonstrated defective RB-pocket binding ac-
tivity in vitro by means of recombinant E2F1 as a target
(fig. 1B). These findings show that three independentRB
alleles, D480, 661W, and 712R, localized to the pocket
domain, share similar biochemical properties that are
distinct fromWT RB and from classic RB null mutations
found in familial retinoblastoma or sporadic adult car-
cinomas (fig. 2).
To further study these low-penetrant alleles, we have
developed a yeast two-hybrid assay and have shown that
the D480 and 661W mutants retain in vivo a basal level
of binding activity to SV40 T antigen that is significantly
reduced but consistently greater than the null binding
activity of the 706F RB mutant (Otterson et al. 1997).
To examine whether the new low-penetrant mutant,
712R, also exhibited a reduced but detectable pocket-
binding activity for large T antigen, we plated indepen-
dent yeast colonies that coexpressed large T antigen with
the 712R mutant fused to a Gal4 DNA-binding domain
and performed a qualitative filter assay for pocket bind-
ing (fig. 3A). In contrast with our earlier data with D480
and 661W (Otterson et al. 1997), both the 712R and
the null 706F mutants had undetectable pocket binding
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Figure 3 A, b-Galactosidase filter analysis for WT and for the
706F and 712R mutants, assayed after growth of cells at either 24C
or 30C, as indicated. Two independent transformants are shown for
each RB cDNA. B, b-Galactosidase filter analysis of WT or the five
different RB point mutants, as indicated. Two independent transfor-
mants are shown for each RB cDNA, and assays were performed after
growth of cells at either 37C, 30C, or 24C. The yellow-green signal
indicates the streaked yeast colonies transferred to the nitrocellulose
filter. The purple-blue signal represents b-galactosidase activity as a
reporter for a protein-binding interaction between the RB clones and
large T antigen.
Table 1
Temperature-Sensitive Binding of Mutant RB Alleles
MEAN  SD b-GALACTOSIDASE ACTIVITY ATa
(% of WT)
cDNA 30C 24C
WT RB 100  21.5 100  24.8
706F .3  .1 .4  .4
707W 53.4  6.3 46.1  4.8
661W 9.4  1.6 57.4  9.6
D480 23.6  2.9 63.9  4.1
712R 1.9  .5 20.6  5.4
a One unit b-galactosidase hydrolyzes 1 mmol ONPG to O-nitro-
phenol and D-galactose/minute/cell.
at the physiological temperature for yeast growth, 30C.
A duplicate plate, however, where the yeast cells had
grown overnight at 24C showed evidence for an inter-
action of the 712R mutant with large T antigen, al-
though the null binding of the 706F mutant was
unaffected.
To extend this observation, we repeated this assay
after an incubation, at 24C, 30C, and 37C, of two
independent yeast transformants that coexpressed large
T antigen with either WT RB, the null 706F mutant, an
adjacent in vitro mutant designated “707W” (Kratzke
et al. 1992), or each of the three low-penetrant RB mu-
tants, D480, 661W, and 712R (fig. 3B). We observed
that all three low-penetrant alleles demonstrated a tem-
perature-sensitive pattern of pocket binding to large T
antigen, with loss of specific binding at 37C and a sug-
gestion of enhanced binding, as compared with WT RB
at 24C. In contrast, the binding of the 706F mutant
and the 707W in vitro mutant were unaffected by in-
cubation at the different temperatures. The reduced
binding of the 712R product is consistent with our ob-
servation that this low-penetrant mutant exhibited a re-
duced level of cyclin-mediated hyperphosphorylation as
compared withWTRB andwith the other low-penetrant
mutants (fig. 1; data not shown).
We confirmed the finding of temperature-sensitive
binding by using a quantitative yeast two-hybrid assay
with six independent measurements for each RBmutant,
to assay b-galactosidase activity per unit time (min) and
per yeast cell (table 1). We observed, as reported else-
where, that the 707W mutant had a moderate reduction
in pocket binding (50% of WT binding activity)
(Kratzke et al. 1992; Otterson et al. 1997), and the 706F
showed undetectable binding at the 30C incubation,
whereas each of the low-penetrant mutants showed a
reduced basal-protein binding, with a range of 1.9%–
23.6% of WT binding (table 1). Simultaneous measure-
ments after a 24C incubation showed a marked en-
hancement of pocket binding for each of the low-pen-
etrant mutants, representing a 2.7-fold increase to 64%
of WT binding for the D480 mutant, a 6.1-fold increase
to 57.4% for the 661Wmutant, and a 10.8-fold increase
to 20.6% for the 712Rmutant. In contrast, no difference
was detected for the 707W mutant (53.4%–46.1%) or
for the 706F mutant (0.3%–0.4% of WT binding).
Discussion
The identification of unique RB mutant alleles that
are present in the germline of families with incomplete
penetrance of familial retinoblastoma is the first example
of a genotype-phenotype relationship within theRB gene
that links clinical findings with biochemical analyses.
From a clinical perspective, these findings emphasize the
importance of cautious genetic counseling of patients
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who present with sporadic, unilateral retinoblastoma,
since they may still harbor a germlineRBmutation (Dra-
per et al. 1992; Klutz et al. 1999). The occasional use
of the phrase “mild expression” as a synonym for low
penetrance of inherited retinoblastoma is premature,
since there is no evidence suggesting that clonally ex-
panded tumors arising within these families are biolog-
ically less aggressive. The key clinical question, therefore,
is, Why do germline carriers of low-penetrantRBmutant
alleles exhibit a reduced number of tumor foci that are
otherwise indistinguishable from sporadic or inherited
retinoblastoma? Inspection of the pedigrees from large
families with incomplete penetrance typically shows an
unpredictably variable frequency of retinal tumor de-
velopment, even within carriers of the samemutant allele
(Onadim et al. 1992; Lohmann et al. 1994; Seminara
and Dryja 1994; Cowell and Bia 1998; Huang et al.
1998). Although this likely represents reduced retinal-
cell tumorigenesis in these families, a component of tu-
mor regression or a block-to-tumor progression may
also participate in the phenotype of low penetrance. For
example, ∼5%–10% of families with a child diagnosed
with retinoblastoma will have at least one other member
diagnosed with unifocal or multifocal retinomas, de-
tected as a nonproliferating retinal scar (Balmer et al.
1991, 1992; Gunalp et al. 1996). In addition, ∼2%–3%
of untreated retinoblastoma tumors are reported to un-
dergo spontaneous regression (Lommatzsch et al. 1993).
Although the presence of retinomas and/or regressed ret-
inal tumors has been detected in otherwise unaffected,
obligate carriers of low-penetrant mutant RB alleles
(Onadim et al. 1992), these lesions have also been ob-
served in classic familial retinoblastoma, and there is no
evidence to date that links this interesting phenomenon
with the phenotype of incomplete penetrance.
To address the molecular basis for low penetrance, we
have studied the biochemical properties of three low-
penetrant RB alleles (D480, 661W, and 712R) that target
single amino acids localized to the RB-pocket domain
and that map to the interface between the A and B do-
mains, which is essential for stabilizing the binding-
pocket cleft localized within the B domain (Lee et al.
1998). Each of these mutants is distinguished from WT
RB by its link to the development of retinoblastoma in
12 families and by evidence of defective RB-pocket bind-
ing by means of standard in vitro pocket-binding assays
(Kratzke et al. 1994; Otterson et al. 1997; see fig. 1B)
and is distinguished from all other null RB mutants by
the retention of several parameters of WT function, in-
cluding the ability to undergo cyclin-dependent, kinase-
mediated–phosphorylation in vivo assays (Kratzke et al.
1994; Otterson et al. 1997; see fig. 1A). In addition, the
661W mutant has been recently shown to suppress col-
ony growth of RB (/) tumor cells and to induce a
pattern of cellular differentiation in SAOS-2 osteosar-
coma cells comparable to that in WT RB, while simul-
taneously behaving as a null mutant in experiments that
measure its ability to induce a cell-cycle G1 arrest or to
repress the E2F1 transcription-factor activity in vivo
(Kratzke et al. 1994; Sellers et al. 1998). These data
suggest, but do not prove, that the partial inactivation
of low-penetrant mutants, such as the 661W allele, may
reflect RB tumor suppressionmediated by specific pocket
binding to non-E2F1 cellular partners that are linked to
a cellular-differentiation pathway. The tumor-suppressor
activity of these alleles, however, is intermittently defec-
tive, as clinically manifested by the development of un-
ifocal and multifocal retinoblastoma tumors in a subset
of germline carriers. The demonstration that the pocket
binding activity of each of these mutants can fluctuate
2.7-fold to 10.8-fold with changes in the ambient con-
ditions of the incubated cells, whereas an adjacent point
mutant (707W) or a null pocket mutant (706F) showed
no fluctuations under the same conditions (table 1), sug-
gests a model where the basal tumor-suppressor pocket
activity of these unstable, single-codon RB mutants is
near a threshold level of pocket protein binding in vivo,
which may be impacted by minor variations in ambient
conditions. It is unlikely, however, that thermal energy
alone would be responsible for affecting protein stability,
since eukaryotic stress responses are coordinated
through a complex family of protein chaperones that
can function to reversibly stabilize mutant proteins
(Chen et al. 1996; Rutherford and Lindquist 1998). In
addition, it is also unlikely that a single model will define
the mechanism for the phenotype of incomplete pene-
trance, since there is already heterogeneity in the clas-
sification of underlying low-penetrant RBmutations. For
example, two additional RB mutations that arise from
large deletions outside the pocket domain have been re-
cently identified in single kindreds with low penetrance
(Dryja et al. 1993; Bremner et al. 1997). These two
mutants, a deletion of exon 4 (Dex4) and a deletion of
exons 24/25 (Dex24/25), exhibit a biochemical pattern
that is distinct from the D480, 661W, and 712Rmutants,
including, in the case of D24/25, a pocket-binding pat-
tern in vitro and with the yeast two-hybrid assay, which
was indistinguishable from WT binding under all con-
ditions of testing (data not shown). Although the un-
derlying defect in the nonpocket, low-penetrant alleles
(Dex 4 and Dex24/25) is different from that in the family
of pocket, temperature-sensitive, low-penetrantmutants,
it is possible that the tumor-suppressor activity exhibited
by each of these mutant RB alleles will ultimately act
through a similar cellular differentiation pathway. The
observation that reversible fluctuations in a threshold
level of RB-pocket binding activity can be demonstrated
in a series of low-penetrant RB alleles suggests that this
protein instability may contribute to the variable fre-
quency of tumor development observed in many of these
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families with the phenotype of incomplete penetrance.
The availability of primary retinoblastoma tumor ma-
terial to examine the mechanism underlying the genetic
inactivation of the remaining WT allele in these affected
subjects, however, will also be important in the devel-
opment of a working model to explain the molecular
basis for incomplete penetrance. Ultimately, understand-
ing the mechanism of tumor suppression for each of
these low-penetrant mutants will help to define more
precisely the functional properties of the RB tumor-sup-
pressor gene and may impact the clinical management
of these families in the future.
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